Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Value-Based Care
The New Era of Personalized Medicine in Oncology: Novel Biomarkers Ushering in New Approaches to Cancer Therapy
By
Steve Stricker, PharmD, MS, BCOP
Value-Based Care
,
VBCC Perspectives
October 2011, Vol 2, No 6
It is next to impossible for a day to go by without thinking about the contributions of personalized medicine to the care of patients living with cancer. Whether we are treating a newly diagnosed patient with HER2/neupositive breast cancer using trastuzumab, or using erlotinib in the management of a patient with non–small-cell lung cancer (NSCLC) whose tumor harbors specific mutations in the epidermal growth factor receptor genes, individualizing therapy based on molecular biology and genetic testing has become commonplace in contemporary oncology practice.
Read Article
Value-Based Insurance Design in Oncology
By
Wayne Kuznar
Economics & Value
,
Value in Oncology
,
Value-Based Care
July 2011, Vol 2, No 4
Philadelphia, PA—The “one-size-fitsall” approach to current benefit designs does not recognize that health services have different levels of value; such an approach, therefore, lacks incentives for patients to adhere to diagnostic tests and treatments with proven effectiveness that may help to contain costs to various healthcare stakeholders.
Read Article
The Challenge of Value-Based Care in Oncology: Improving Clinical Outcomes
Economics & Value
,
Value-Based Care
,
VBCC Perspectives
June 2011, Vol 2, No 3
The focus on value in patient care has taken a prominent place in any discussion related to improving care delivery, but no agreement exists on what that “value” is.
Read Article
The Potential for Personalized Medicine to Improve the Value of Targeted Therapy
By
Yu-Ning Wong, MD, MSCE
Economics & Value
,
Value-Based Care
,
VBCC Perspectives
April 2011, Vol 2, No 2
Read Article
The Costs of Care: A Discussion We’re Not Prepared to Have—Yet
By
Denise K. Pierce
Value-Based Care
,
VBCC Perspectives
November/December 2010, Vol 1, No 6
Each year, oncologists return to their respective practices after attending the annual American Society of Clinical Oncology or American Society of Hematology meetings armed with knowledge of new drug/biologic combinations, modified regimen dosing, and other novel approaches that may provide incrementally better outcomes for cancer patients.
Read Article
New Prostate Cancer Therapies Raise New Issues
By
Lee N. Newcomer, MD, MHA
Value-Based Care
,
VBCC Perspectives
September 2010, Vol 1, No 4
Prostate cancer patients have 2 new therapeutic options this summer with the approvals of sipuleucel-T and cabazitaxel. The former drug is an important scientific advance as one of the pioneering cancer vaccines to show a prolongation of survival.
Read Article
The $93,000 Question
By
Yu-Ning Wong, MD, MSCE
Value-Based Care
,
VBCC Perspectives
September 2010, Vol 1, No 4
Sipuleucel-T (Provenge) and cabazitaxel (Jevtana) have drawn much attention both for being the first new treatments for advanced prostate cancer since docetaxel (Taxotere) was approved in 2004, and for their high costs. As described in Dr Newcomer’s accompanying piece, they will add significantly to the cost of care for prostate cancer patients.
Read Article
Community Trials Essential to Broad Knowledge
By
Ed Pezalla, MD, MPH
Value-Based Care
,
VBCC Perspectives
September 2010, Vol 1, No 4
Several sessions at the recent ASCO meeting considered new standards for community-based oncology research and the development of comparative effectiveness research (CER) methods.
Read Article
Premarket Policies May Generate the Best Value
By
Jayson Slotnik, JD, MPH
Value-Based Care
,
VBCC Perspectives
June 2010, Vol 1, No 2
The Patient Protection and Affordable Care Act (PPACA), which is Congress’ latest attempt to reform our healthcare system, creates 3 new entities that will test new payment methodologies or compare current treatments in an attempt to determine better value for our healthcare dollar.
Read Article
Reaching for Consistency with Genetic Testing
By
Winston Wong, PharmD
Value-Based Care
,
VBCC Perspectives
June 2010, Vol 1, No 2
Recent articles in the
New England Journal of Medicine
1
and the
Journal of the American Medical Association
2
note the tremendous increase in the cost of cancer care, which has at least doubled since 1990. The reasons for this steep increase have been attributed to the release and utilization of new medications, in tandem with more sophisticated surgery and radiation techniques.
Read Article
Page 11 of 12
3
4
5
6
7
8
9
10
11
12
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma